ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)

The ESMO-MCBS is a standardised, generic, validated approach to stratify
the magnitude of clinical benefit that can be anticipated from anti-cancer therapies.

ESMO-MCBS

The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.

The ESMO-MCBS is an important first step to the critical public policy issue of value in cancer care, helping to frame the appropriate use of limited public and personal resources to deliver cost effective and affordable cancer care.

The ESMO-MCBS is a dynamic tool and its criteria revised on a regular basis.

Score Cards

The ESMO-MCBS Score Card allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Introducing the ESMO-Magnitude of Clinical Benefit Scale

Fortunato Ciardiello, Elisabeth de Vries, Josep Tabernero and Alexandru Eniu introduce The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) – a standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies.

ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS)

ESMO-MCBS

The scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from anti-cancer treatments.

Clinical Practice Guidelines News

Scale Evaluation Forms v1.0 & v1.1

Score Cards

Introducing the ESMO-Magnitude of Clinical Benefit Scale

Articles in ESMO Journals

Presentations

Magnitude of Clinical Benefit Scale Working Group